Primary immunodeficiencies (PIDs), also known as inborn errors of immunity (IEI), are a group of more than 400 potentially serious disorders, that can lead to frequent or severe infections, swellings and autoimmune problems. Symptoms often appear in childhood, but some can first occur in adults.
29 April 2022
The ASCIA Immunodeficiency Strategy for Australia and New Zealand was developed by ASCIA, the peak professional body of clinical immunology and allergy specialists in Australia and New Zealand, in consultation with patient organisations (AusPIPs, HAE Australasia, IDFA and IDFNZ), and other stakeholders. Whilst the main content of the Strategy was completed in November 2020, the final version of the Strategy is now available, to coincide with the International Day of Immunology and World PID Week.
ASCIA continues to update its information about COVID-19 vaccination and immunodeficiencies, which is available on the ASCIA COVID-19 webpage www.allergy.org.au/members/covid-19
Since 2019 ASCIA has worked in collaboration with patient organisations and other stakeholders to develop a ASCIA Immunodeficiency Strategy at a national level for both Australia and New Zealand.
The ASCIA Immunodeficiency Strategy’s purpose is to improve the health and wellbeing of people with PIDs (primary immunodeficiencies) and minimise the burden on individuals, carers, health services and community.
The ASCIA Immunodeficiency Strategy for Australia and New Zealand has the purpose to improve the health and wellbeing of people with primary immunodeficiencies (PID), also known as inborn errors of immunity (IEI), and minimise the burden on individuals, carers, health services and community.